 |
|
Analysis of T-Cell Receptor Gene Rearrangement in Lymph Nodes of Patients With Mycosis Fungoides
Prognostic Implications
Donald E. Kern, MD, PhD;
Pamela G. Kidd, MD;
Roger Moe, MD;
Deena Hanke, MS;
John E. Olerud, MD
Arch Dermatol. 1998;134:158-164.
Objective To determine the prognostic value of analyzing lymph node (LN) DNA from patients with mycosis fungoides for the presence of a monoclonal T-cell population.
Design Inception cohort study.
Setting A tertiary care referral center in Seattle, Wash.
Patients Fifty-five uniformly staged patients with the diagnosis of mycosis fungoides and who had a lymph node biopsy, 21 with clinically abnormal nodes and 34 with normal nodes.
Main Outcome Measures Lymph nodes were evaluated by Southern blot analysis for T-cell receptor  -chain (TCRB) gene rearrangement and by histopathologic examination for the LN classification using the National Cancer Institute system. Patients were observed clinically for a mean (±SD) of 4.7±3.4 years.
Results Patients with detectable TCRB gene rearrangement in lymph node DNA had an increased likelihood of a poor clinical outcome and a decreased probability of survival (P<.001 for both) compared with patients with the TCRB germline. Although patients with clinically enlarged nodes were more likely to have the TCRB gene rearranged, those with normal nodes and the TCRB gene rearranged also had a poor clinical outcome and a decreased probability of survival. Similar to those with the TCRB gene rearranged, most patients with advanced histopathologic changes (LN3 and LN4) had a poor prognosis. The presence of a rearranged TCRB gene, however, correctly predicted some patients with intermediate LN scores (LN2) who had a poor clinical outcome.
Conclusions Detection of a monoclonal T-cell population, as demonstrated by a rearranged TCRB gene on Southern blot analysis, in LNs of patients with mycosis fungoides is predictive of a poor clinical outcome and a reduced probability of survival. Lymph node TCRB gene analysis provides additional prognostic information for patients with mycosis fungoides with intermediate LN histopathology.
From the Division of Dermatology, Department of Medicine (Drs Kern and Olerud), and the Departments of Laboratory Medicine (Dr Kidd and Ms Hanke) and Surgery (Dr Moe), University of Washington School of Medicine, Seattle; and the Department of Pathology, Robert Wood Johnson University Hospital, New Brunswick, NJ (Dr Kidd).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Using Molecular Biologic Analysis of T-Cell Receptor Gene Rearrangements to Stage Cutaneous T-Cell Lymphoma
Gary S. Wood
Arch Dermatol. 1998;134(2):221-223.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography.
Tsai et al.
Arch Dermatol 2006;142:577-584.
ABSTRACT
| FULL TEXT
Analysis of T-Cell Receptor Gene Rearrangement for Predicting Clinical Outcome in Patients With Cutaneous T-Cell Lymphoma: A Comparison of Southern Blot and Polymerase Chain Reaction Methods
Juarez et al.
Arch Dermatol 2005;141:1107-1113.
ABSTRACT
| FULL TEXT
Early TCR-{beta} and TCR-{gamma} PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications
Assaf et al.
Blood 2005;105:503-510.
ABSTRACT
| FULL TEXT
T-Cell Receptor and Immunoglobulin Gene Rearrangements in Diagnosing Skin Disease
Wood
Arch Dermatol 2001;137:1503-1506.
FULL TEXT
Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma
Scarisbrick et al.
Blood 2001;97:624-630.
ABSTRACT
| FULL TEXT
An Update on Treating Cutaneous T-Cell Lymphoma
Journal Watch Dermatology 1999;1999:10-10.
FULL TEXT
Using Molecular Biologic Analysis of T-Cell Receptor Gene Rearrangements to Stage Cutaneous T-Cell Lymphoma
Wood
Arch Dermatol 1998;134:221-223.
FULL TEXT
|
